4.3 Article

Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma

Journal

ONCOTARGET
Volume 6, Issue 19, Pages 17805-17816

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4596

Keywords

NF-kappa B; glioblastoma; TRADD; microRNA-31

Funding

  1. National Institutes of Health [T32NS048039, R01CA158534, R01CA138517]
  2. American Brain Tumor Association Basic Research Fellowship in Honor of Paul Fabbri
  3. Southeastern Brain Tumor Foundation
  4. UAB Comprehensive Cancer Center

Ask authors/readers for more resources

Glioblastomas (GBMs) are deadly tumors of the central nervous system. Most GBM exhibit homozygous deletions of the CDKN2A and CDKN2B tumor suppressors at 9p21.3, although loss of CDKN2A/B alone is insufficient to drive gliomagenesis. MIR31HG, which encodes microRNA-31 (miR-31), is a novel non-coding tumor suppressor positioned adjacent to CDKN2A/B at 9p21.3. We have determined that miR-31 expression is compromised in >72% of all GBM, and for patients, this predicts significantly shortened survival times independent of CDKN2A/B status. We show that miR-31 inhibits NF-kappa B signaling by targeting TRADD, its upstream activator. Moreover, upon reintroduction, miR-31 significantly reduces tumor burden and lengthens survival times in animal models. As such, our work identifies loss of miR-31 as a novel non-coding tumor-driving event in GBM.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available